Middle East & Africa Antiviral Drugs Market Size & Outlook
Middle East & Africa antiviral drugs market, 2018-2030 (US$M)
Related Markets
MEA antiviral drugs market highlights
- The MEA antiviral drugs market generated a revenue of USD 2,405.4 million in 2022.
- The market is expected to grow at a CAGR of -5.3% from 2023 to 2030.
- In terms of segment, hiv was the largest revenue generating application in 2022.
- HIV is the most lucrative application segment registering the fastest growth during the forecast period.
- Country-wise, UAE is expected to register the highest CAGR from 2023 to 2030.
MEA data book summary
| Market revenue in 2022 | USD 2,405.4 million |
| Market revenue in 2030 | USD 1,557.7 million |
| Growth rate | -5.3% (CAGR from 2022 to 2030) |
| Largest segment | Hiv |
| Fastest growing segment | HIV |
| Historical data covered | 2018 - 2021 |
| Base year for estimation | 2022 |
| Forecast period covered | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | HIV, Hepatitis, Herpes, Influenza |
| Key market players worldwide | Roche Holding AG, GSK PLC ADR, AbbVie Inc, Merck & Co Inc, Johnson & Johnson, Bristol-Myers Squibb Co, Dr Reddy's Laboratories Ltd ADR, Aurobindo Pharma |
Other key industry trends
- In terms of revenue, MEA region accounted for 3.3% of the global antiviral drugs market in 2022.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 8,502.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antiviral Drugs Market Scope
Antiviral Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Middle East & Africa antiviral drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to antiviral drugs market will help companies and investors design strategic landscapes.
Hiv was the largest segment with a revenue share of 30.97% in 2022. Horizon Databook has segmented the Middle East & Africa antiviral drugs market based on hiv, hepatitis, herpes, influenza covering the revenue growth of each sub-segment from 2018 to 2030.
Major markets in the MEA region include South Africa, Saudi Arabia, the UAE, and Kuwait. MEA is expected to show a negative CAGR which is attributable to a steep rise in revenue during COVID-19. The decline in CAGR for other diseases is attributable to a lack of disease diagnosis & treatment along with the declining prevalence of viral infections in the regions such as Saudi Arabia and UAE.
However, the increased prevalence of flu and the risk of seasonal influenza in some countries in MEA are propelling the market growth in the region. In addition, an increase in government initiatives and a rise in partnerships of key players with healthcare providers are anticipated to boost the market over the forecast period.
Reasons to subscribe to Middle East & Africa antiviral drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Middle East & Africa antiviral drugs market databook
-
Our clientele includes a mix of antiviral drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa antiviral drugs market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa antiviral drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
MEA antiviral drugs market size, by country, 2018-2030 (US$M)
Middle East & Africa Antiviral Drugs Market Outlook Share, 2022 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
